Evidence map›Paper›PMID 41692829›Full record

ArticleNature communications2026

Biomimetic metal-drug coordination nanoplatform to counteract drug resistance in Pseudomonas aeruginosa via energy disruption.

Yingmin Ye, Kai Zhang, Yanmin Wang, Yang Li, Nana Zhao, Fu-Jian Xu

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yingmin YeState Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, China.
Kai ZhangState Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, China. zhangk@mail.buct.edu.cn.ORCID http://orcid.org/0000-0003-3761-3209
Yanmin WangState Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, China.
Yang LiState Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, China.ORCID http://orcid.org/0000-0002-6493-3972
Nana ZhaoState Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, China. zhaonn@mail.buct.edu.cn.ORCID http://orcid.org/0000-0001-8610-3411
Fu-Jian XuState Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, China. xufj@mail.buct.edu.cn.ORCID http://orcid.org/0000-0002-1838-8811

Funding

National Natural Science Foundation of China (National Science Foundation of China) 52221006National Natural Science Foundation of China (National Science Foundation of China) 52293382National Natural Science Foundation of China (National Science Foundation of China) 52303172National Natural Science Foundation of China (National Science Foundation of China) 52361165659Natural Science Foundation of Beijing Municipality (Beijing Natural Science Foundation) 2262072
6 · The paper itself

Abstract

The rapid emergence of antimicrobial resistance is a critical global health challenge that renders conventional antibiotics ineffective. Developing innovative strategies to resensitize drug-resistant pathogens to existing antibiotics represents a promising therapeutic approach. Here, we present a biomimetic nanoplatform (Ce-Car@EV NPs) through the rational integration of ginger-derived extracellular vesicles (EVs) and a pH-responsive cerium-carbenicillin coordination nanoparticles (Ce-Car NCPs). This design enables prolonged circulation and targeted degradation in acidic infection sites, releasing Ce

Indexed as

Anti-Bacterial AgentsBiomimetic MaterialsDrug Resistance, BacterialPseudomonas aeruginosaAdenosine TriphosphateAnimalsBiomimeticsCarbenicillinCeriumMicrobial Sensitivity TestsNanoparticlesPseudomonas InfectionsAdenosine TriphosphateAnti-Bacterial AgentsCarbenicillinCerium

Identifiers

PMID41692829
PMCPMC13022498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.